Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 plus atezolizumab versus standard of care as first-line treatment for extensive-stage small cell lung cancer
MOH_2025-11-11_015453Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of turmetabart adizutecan and atezolizumab in small cell lung cancer (SCLC) (3 arms), sponsored by AbbVie Inc. Started Nov 2025; status: recruiting.
02
Drugs
turmetabart adizutecanatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2025-11-11_015453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-11_015453.